top of page
Bound-logo.png
Bound Therapeutics is developing next-generation RNA therapies for aggressive cancers and rare diseases using its AI-driven Magic Bullet Designer™ platform. By combining targeted delivery with precision peptide engineering, Bound is creating antisense therapeutics with improved efficacy, safety, and personalization—aiming to transform treatment for underserved patient populations.

Lead Program & Pipeline

  • Lead molecule: Antisense oligonucleotide targeting aggressive cancers, including triple-negative breast cancer (TNBC)

  • Developed with Magic Bullet Designer™ (MBD), a proprietary AI-driven RNA delivery platform

  • Pipeline expansion planned for lung, colon cancers, and genetic disorders

  • Future programs to target inflammatory and neurodegenerative diseases

Technology Differentiators

  • Cancer-specific RNA delivery minimizes toxicity and preserves immune function

  • Uses peptide ligand–based targeting for tissue precision

  • Combines antisense RNA analogs with AI/ML optimization

  • Enables personalized treatment through companion diagnostics and biomarker integration

Stage & Investment

  • Stage: Preclinical

  • Funding Raised: <$500K

  • IP: One issued patent; one PCT filed in 2024

  • Current Funding Goal: $3–4M seed round to complete IND-enabling studies and scale manufacturing

  • Collaborators: Charles River, PeptiStar, Millipore Sigma, WuXi AppTec, Eureka Biotechnology, Riken Genesis

What's Next

  • Initiate IND-enabling studies and preclinical safety evaluation in two species

  • Complete IND submission package for FDA

  • Engage in regulatory consultations (Pre-IND, Orphan Drug, Fast Track designation)

  • Raise Series A post-IND to begin Phase I trials

Leadership

Crystal-Jin.jpg
Crystal Jin, PhD 
CEO & Co-founder
Eric-Wickstrong.jpg
Eric Wickstrom, PhD
CSO & Co-founder
bottom of page